LGALS9 and B-cell chronic lymphocytic leukemia: At the endpoint of the experiment, 7 weeks after TCL1 AT, a reduced spleen weight and lower numbers of CLL cells were detected in the spleen and lymph nodes of the mice receiving anti-galectin-9 (Fig. 7G, Supplementary Fig. 10E).